The Lymph2Cx test, which is the first test to go into practice from the Mayo Clinic Molecular Diagnostic Arizona Laboratory, is a genetic test that guides diagnosis and treatment of patients with diffuse large B-cell lymphoma, the most common type of non-Hodgkin’s lymphoma.
“New tests like this help us identify accurate diagnoses and treatments quickly, saving time and money, and, ultimately, transforming patient care,” said Keith Stewart, the Carlson and Nelson Endowed Director of the Mayo Clinic Center for Individualized Medicine.
This test will first be deployed at Mayo Clinic’s Arizona campus, followed by its Florida and Minnesota campuses.
More articles on health IT:
Silver Cross Hospital, Teladoc partner for telehealth
The growth of telehealth: 20 things to know
Parkridge West Hospital provides stroke care via telemedicine
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.